Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 4,139 Shares

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 4,139 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $5.08, for a total transaction of $21,026.12. Following the completion of the transaction, the insider directly owned 589,046 shares in the company, valued at $2,992,353.68. This trade represents a 0.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total value of $42,800.47.
• On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total value of $32,218.36.
• On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The stock was sold at an average price of $5.27, for a total value of $29,280.12.
• On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The shares were sold at an average price of $5.32, for a total transaction of $67,377.80.
• On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The stock was sold at an average price of $5.05, for a total transaction of $61,200.95.
• On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The stock was sold at an average price of $4.80, for a total value of $59,673.60.
• On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The shares were sold at an average price of $5.13, for a total transaction of $40,644.99.
• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The shares were sold at an average price of $5.10, for a total value of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The stock was sold at an average price of $5.12, for a total value of $100,459.52.
• On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The shares were sold at an average price of $4.89, for a total transaction of $127,653.45.

Clene Stock Performance

NASDAQ CLNN traded down $0.28 on Wednesday, reaching $4.91. The company’s stock had a trading volume of 92,400 shares, compared to its average volume of 124,439. Clene Inc. has a twelve month low of $2.28 and a twelve month high of $13.50. The firm’s 50 day moving average is $6.61 and its two-hundred day moving average is $6.55. The stock has a market cap of $53.27 million, a PE ratio of -1.45 and a beta of 0.87.

Clene (NASDAQ:CLNN) last posted its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. Equities research analysts anticipate that Clene Inc. will post -5.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Benchmark reissued a “buy” rating on shares of Clene in a research report on Thursday, December 4th. UBS Group restated a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. D. Boral Capital reissued a “buy” rating and issued a $23.00 price objective on shares of Clene in a report on Friday, January 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.60.

Hedge Funds Weigh In On Clene

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp acquired a new position in shares of Clene during the 3rd quarter valued at $29,000. Jane Street Group LLC bought a new position in Clene during the second quarter worth about $47,000. Lunt Capital Management Inc. increased its position in shares of Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after buying an additional 21,217 shares during the period. Finally, Scoggin Management LP grew its holdings in shares of Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after purchasing an additional 42,750 shares in the last quarter. 23.28% of the stock is owned by institutional investors and hedge funds.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).